Orphan designation: Glucagon, Treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome, 19/11/2018, Positive
On 19 November 2018, orphan designation (EU/3/18/2091) was granted by the European Commission to Pharma Gateway AB, Sweden, for glucagon for the treatment of noninsulinoma pancreatogenous hypoglycaemia syndrome.
The sponsorship was transferred to S-cubed Pharmaceutical Services ApS, Denmark, in February 2019.
Legal Disclaimer:
EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.
